國家衛生研究院 NHRI:Item 3990099045/9571
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 955988      線上人數 : 833
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/9571


    題名: JAK2 overexpression is a prognostic indicator for worse outcome in nasopharyngeal carcinoma and is independent of JAK2 exon 12 and JAK2 V617F mutation
    其他題名: Abstract number
    作者: Liang, PI;Li, CF
    貢獻者: National Institute of Cancer Research
    摘要: Background: The nasopharyngeal carcinoma (NPC) has distinct incidence in various races and different geographical regions. It is endemic in southern China, Southeast Asia, and the Middle East. The etiology of NPC is likely multifactorial, which include genetic susceptibility, infection by Epstein-Barr virus (EBV), and environmental factors. There are several molecular pathways involved in the pathogenesis of NPC. JAK2 is one of the four members of the Janus kinase (JAK) family, and its mutation is an important oncogenic driver in myeloproliferative neoplasms and certain hematopoietic malignancies. By using public domain datasets and our well-characterized cohort, we intended to analyze the association of JAK2 expression in NPC. Design: Two datasets from GEO (GSE12452 and GSE34573) were used to analyze the significance of JAK2 transcript expression between tumor and non-tumor specimen. JAK2 immunostain was performed on 124 cases of NPC and interpreted using H-score. The result was then correlated with clinicopathological features, disease-specific survival (DSS), distal metastasis-free survival (DMeFS), and local recurrence-free survival (LRFS). Twenty NPC cases with JAK2 overexpression were also submitted for JAK2 exon 12 and JAK2 V617F mutation analyses using PCR followed by direct sequencing. Results: Validation of the datasets in public domain showed that, in contrast with non-tumor specimens, there is an up-regulation of JAK2 transcript in NPC. In the immunohistochemical study, JAK2 overexpression significantly associated with advanced disease stage (stage I-II vs stage III-IV, p = 0.019). Its overexpression also independently predict poor DSS (p =0.005), DMeFS (p =0.036), and LRFS (p =0.012). None of the 20 JAK2 overexpressed NPC cases have JAK2 exon 12 and JAK2 V617F mutation. Conclusions: JAK2 overexpression is associated with advanced disease stage and conferred poor clinical outcome, justifying that JAK2 is a potential prognostic biomarker of NPC. Its overexpression is also independent of JAK2 exon 12 and JAK2 V617F mutation.
    日期: 2016-02
    關聯: Laboratory Investigation. 2016 Feb;96(Suppl. 1):325A.
    Link to: http://dx.doi.org/10.1038/labinvest.2016.12
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0023-6837&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000369270702032
    顯示於類別:[其他] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000369270702032.pdf245KbAdobe PDF443檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋